Fig. 2

Development of reduced and total (oxidized + reduced) hIL-33 ELISAs. A Schematic representation of reduced hIL-33 ELISA format: in-house rat anti-hIL-33 15.21C7 capture MAb (dark blue), in-house reduced hIL-33 standard (purple), and in-house biotinylated rat/human chimeric anti-hIL-33 3F10 detection MAb (light blue). B Comparison of standard curves obtained with reduced hIL-33 (blue), oxidized hIL-33 (red), reduced hIL-33 + 20 ng/mL hsST2 (light blue), reduced hIL-33 + 40 ng/mL hsST2 (green). C Schematic representation of total hIL-33 ELISA format: in-house rat anti-hIL-33 15.21C7 capture MAb (dark blue) and R&D System’s goat anti-hIL-33 PAb (orange), in-house reduced hIL-33 (purple) and oxidized hIL-33 (light purple) standards in the presence of hsST2 (gray), and R&D System’s biotinylated goat anti-hST2 (green) and goat anti-hIL-33 (orange) PAbs. D Comparison of reduced and oxidized hIL-33 standard curves in presence of 20 ng/mL hsST2. Data are representative of three experiments performed in duplicates. E Specificity of total hIL-33 ELISA determined by immunodepletion of reduced and oxidized hIL-33 in diluted human VH samples using beads conjugated to hIL-33 Ab. P = 0.0019. Data are means ± SD of duplicates